Major drugmakers and top agencies alike earned their flowers at the annual Fierce Pharma Marketing Awards gala in ...
GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk. | GSK is ...
The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...
UK pharma major GSK (LSE: GSK) is preparing to ask US regulators to widen the use of its ROS1 inhibitor Jideytro (zidesamtinib) to patients starting treatment for the first time, after fresh results ...
GSK is consolidating its vaccine manufacturing operations to one site—located in Canada—amid what a spokesperson said is ...
UK pharma major GSK today announced it has entered an agreement to acquire a potential best-in-class trispecific T ...
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership ...
GlobalData on MSN
GSK bolsters oncology pipeline with $750m Chimagen TCE deal
GSK plans to take the TCE to Phase I clinical trials in multiple myeloma during 2027.
The acquisition is the latest in a string of major licensing deals involving Chinese biotechnology firms ...
GSK’s risvutatug rezetecan (ris-rez) has achieved a median overall survival (OS) of 18.5 months in a phase 3 trial, painting ...
GSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start ...
GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results